


In the claims:

1. (Currently Amended) A compound of formula (I)



(I)

X is CH<sub>2</sub> or SO<sub>2</sub>

R<sup>1</sup> is an optionally substituted aryl;

R<sup>2</sup> is carboxy, cyano, C(O)CH<sub>2</sub>OH, CONHR<sup>8</sup>, SO<sub>2</sub>NHR<sup>9</sup>, tetrazol-5-yl, or SO<sub>3</sub>H

where R<sup>8</sup> is selected from hydrogen, alkyl, aryl, cyano, hydroxy, SO<sub>2</sub>R<sup>12</sup> where R<sup>12</sup> is alkyl, aryl, heteroaryl, or haloalkyl, or R<sup>8</sup> is a group (CHR<sup>13</sup>)<sub>r</sub>COOH where r is an integer of 1-3 and each R<sup>13</sup> group is independently selected from hydrogen or alkyl; R<sup>9</sup> is hydrogen, alkyl, optionally substituted aryl such as optionally substituted phenyl or optionally substituted heteroaryl such as 5 or 6 membered heteroaryl groups, or a group COR<sup>14</sup> where R<sup>14</sup> is alkyl, aryl, heteroaryl or haloalkyl;


R<sup>3</sup> is hydrogen, a functional group, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted alkoxy, optionally substituted aralkyl, optionally substituted aralkyloxy or optionally substituted cycloalkyl;

R<sup>4</sup> is a group NHCOR<sup>15</sup> or NHSO<sub>2</sub>R<sup>15</sup> where R<sup>15</sup> is optionally substituted alkyl, or optionally substituted aryl or optionally substituted heteroaryl;

R<sup>5</sup>, R<sup>6</sup> and R<sup>7</sup> are independently selected from hydrogen, a functional group or an optionally substituted hydrocarbyl group;

and further provided that when R<sup>4</sup> is a group NHCOR<sup>15</sup>, R<sup>15</sup> is substituted alkyl, optionally substituted aryl or optionally substituted heteroaryl.

2. (Previously Presented) A compound according to claim 1 wherein a group  $R^{15}$  as it appears in the definition of  $R^4$ , is substituted by at least one functional group, or an aryl or heterocyclyl group, either of which may themselves be substituted by one or more functional groups or further aryl or heterocyclyl groups.
3. (Previously Presented) A compound according to claim 1 wherein  $R^{15}$  is a substituted alkyl group or an optionally substituted heterocyclyl or optionally substituted phenyl group.
4. (Previously Presented) A compound according to claim 3 wherein  $R^{15}$  is alkyl substituted by a group of formula  $NR^{19}R^{20}$  where  $R^{19}$  and  $R^{20}$  are independently selected from hydrogen or optionally substituted hydrocarbyl, or  $R^{19}$  and  $R^{20}$  together form an optionally substituted ring which optionally contains further heteroatoms such as  $S(O)_m$ , oxygen and nitrogen, n is an integer of 1 or 2, and m is 1 or 2.
5. (Previously Presented) A compound according to claim 1, where  $R^2$  is carboxy.
6. (Previously Presented) A compound according to claim 1 wherein  $R^1$  is 3,4-dichlorophenyl, 3-fluoro-4-chlorophenyl, 3-chloro-4-fluorophenyl or 2,3-dichloropyrid-5-yl.
7. (Previously Presented) A compound according to claim 1, where X is  $CH_2$ .
8. (Currently Amended) A process for preparing a compound according to claim 1, which process comprises  
reacting a compound of formula (VII)



(VII)

where X, R<sup>1</sup>, R<sup>3</sup>, R<sup>5</sup>, R<sup>6</sup> and R<sup>7</sup> are as defined in claim 1, and R<sup>2</sup> is a group R<sup>2</sup> as defined in relation to formula (I) or a protected form thereof, with a compound of formula (VIII)



(VIII)

where Z is a leaving group and R<sup>22</sup> is a group ~~COR<sup>15'</sup>~~ or SO<sub>2</sub>R<sup>15'</sup> where R<sup>15'</sup> is group R<sup>15</sup> as defined in relation to formula (I) or a precursor thereof;

and thereafter if desired or necessary:

- (i) converting a precursor group R<sup>15'</sup> to a group R<sup>15</sup> and/or converting a group R<sup>15</sup> to a different ~~such group R<sup>15</sup>~~; and
- (ii) deprotecting a group R<sup>2'</sup> to a group R<sup>2</sup>.

9. (Previously Presented) A pharmaceutical composition comprising a compound according to claim 1 in combination with a pharmaceutically acceptable carrier.

10. (Previously Presented) A method for antagonizing an MCP-1 (Monocyte Chemoattractant Protein-1) or RANTES (Regulated upon Activation, Normal T-cell Expressed and Secreted) mediated effect in a warm blooded animal in need of such treatment comprising administering to said animal an effective amount of a compound according to claim 1, a pharmaceutically acceptable salt, or an *in vivo* hydrolysable ester thereof.

11. (Previously Presented) A method for treating inflammation in a warm blooded animal in need of such treatment comprising administering to said animal an effective amount of a compound according to claim 1, a pharmaceutically acceptable salt, or an *in vivo* hydrolysable ester thereof.